(Q39696541)

14 September 2017

1 reference

title

Drug delivery to macrophages for the therapy of cancer and infectious diseases (English)

1 reference

14 September 2017

1 reference

Kirsh R

1

1 reference

14 September 2017

Bugelski PJ

series ordinal

2

1 reference

14 September 2017

Poste G

series ordinal

3

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 January 1987

1 reference

Annals of the New York Academy of Sciences

14 September 2017

published in

1 reference

14 September 2017

volume

507

1 reference

14 September 2017

page(s)

141-154

1 reference

Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Synthetic immunostimulants derived from the bacterial cell wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Effect of Muramyl Dipeptide Analog onSalmonella enteritidisInfection in Beige Mice with Chediak-Higashi Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Effects of treatment with muramyl dipeptide on resistance to Mycobacterium leprae and Mycobacterium marinum infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Cell surface receptors for lymphokines. I. The possible role of glycolipids as receptors for macrophage migration inhibitory factor (MIF) and macrophage activation factor (MAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Evidence for the identity of murine gamma interferon and macrophage activating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1987.TB45797.X

10.1111/J.1749-6632.1987.TB45797.X

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference